Original Article

Relationship between maternal arterial and foetal cord carbon dioxide tension and neonatal outcome in critically ill pregnant women at delivery

Address for correspondence:

Dr. Bhavani S Kodali, Department of Anesthesiology, University of Maryland, 22 S. Greene St., S11B, Baltimore, MD 21201, United States. E-mail: bkodali@som. umaryland.edu

> Submitted: 15-Dec-2023 Revised: 24-Jan-2024 Accepted: 24-Jan-2024 Published: 13-Mar-2024

Access this article online

Website: https://journals.lww. com/ijaweb

DOI: 10.4103/ija.ija_1218_23

Quick response code



Katelyn T Scharf, Shobana Bharadwaj, Allison Lankford¹, Michael Wong, Bhavani S Kodali

Departments of Anesthesiology and ¹Obstetrics and Gynecology, University of Maryland School of Medicine, Baltimore, MD, United States

ABSTRACT

Background and Aims: No studies have evaluated the relationship between maternal arterial partial pressure of carbon dioxide (mPaCO₂) and umbilical cord venous partial pressure of carbon dioxide (PCO₂) in critically ill pregnant women at delivery. Based on the studies in healthy pregnant women, an mPaCO₂ target of \leq 50 mmHg is a suggested threshold during mechanical ventilation in critically ill parturients. We evaluated the relationship between mPaCO, and neonatal cord gases in critically ill parturients at delivery as the primary objective. The relationship between mPaCO and APGAR scores at delivery was also analysed as a secondary objective. Methods: Maternal and neonatal cord gas data at delivery and APGAR scores were obtained by a retrospective chart review of 25 consecutive parturients with severe respiratory compromise who were delivered during mechanical ventilation. Linear regression was used to assess the relationship between mPaCO, and umbilical artery and vein PCO, and between mPaCO, and APGAR scores at 1 and 5 min. Results: There was a positive correlation between mPaCO₂ and neonatal cord venous PCO_2 (P = 0.013). Foetal venous PCO_2 exceeded predelivery mPaCO₂ by 17.5 (7.5) mmHg. There was an inverse relationship between mPaCO₂ and neonatal APGAR scores at 1 and 5 min (P = 0.006 and P = 0.007, respectively). **Conclusion:** Foetal cord venous PCO₂ can be predicted if mPaCO₂ values are known. Unlike in healthy pregnant women, there was an inverse relationship between rising mPaCO, levels and neonatal APGAR scores in critically ill pregnant women who had several associated compounding factors.

Keywords: APGAR score, artificial, carbon dioxide, critical illness, infant, linear models, newborn, pregnancy, respiration, umbilical arteries

INTRODUCTION

Permissive hypercapnia remains controversial in parturients with severe acute respiratory distress syndrome (ARDS). Based on very scant data, the maternal arterial partial pressure of carbon dioxide (mPaCO₂) has conventionally been recommended to be maintained below 50 mmHg.^[1] Such a threshold was reported by observations of transient hypercarbia in healthy parturients undergoing vaginal delivery with methoxyflurane anaesthesia.^[2] The transient hypercarbia was beneficial and resulted in babies born with good APGAR scores.^[2] The applicability of these data to critical illness and mechanical ventilation is unclear. Thus, while it is known that maternal hyperventilation can lead to foetal hypoxaemia, the effects of hypoventilation remain unknown.^[3] There are no studies where the foetal blood gas data was evaluated against the mPaCO₂

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

How to cite this article: Scharf KT, Bharadwaj S, Lankford A, Wong M, Kodali BS. Relationship between maternal arterial and foetal cord carbon dioxide tension and neonatal outcome in critically ill pregnant women at delivery. Indian J Anaesth 2024;68:354-9.

© 2024 Indian Journal of Anaesthesia | Published by Wolters Kluwer - Medknow

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

status at the time of the delivery in critically ill pregnant women requiring mechanical ventilation. In addition, no studies have assessed the relationship between mPaCO₂ and APGAR scores at delivery in critically ill pregnant women. Furthermore, little relevant data is available to guide ventilation management during ARDS in pregnant patients, and lung protective ventilation strategies have not been assessed in pregnancy.^[3]

We evaluated the relationship between $mPaCO_2$ and umbilical cord venous and arterial gases at delivery in critically ill pregnant women during mechanical ventilation as the primary outcome. The relationship between $mPaCO_2$ and APGAR scores was also analysed as a secondary outcome.

METHODS

This retrospective study was conducted after obtaining approval from the Institutional Review Board (IRB) of the University of Maryland, Baltimore, MD, USA (vide approval number HP-00091060, dated 6 May 2020). The IRB waived the written informed consent. This retrospective study included all pregnant patients with severe ARDS, admitted from March 2020 through January 2022, who delivered on mechanical ventilation and/or venovenous extracorporeal membrane oxygenation (VV-ECMO).

Lung protective ventilation strategies that followed the ARDS network protocol were used in all parturients. The intensivist chose the ventilation mode (i.e., volume control, pressure control and pressure-regulated volume control). In addition, a proning protocol was used (16 h prone and 8 h supine). Neuromuscular blockade with cisatracurium or rocuronium was also utilised. For parturients whose ARDS worsened despite maximum ventilator settings, VV-ECMO or delivery was considered.

On admission, several critically ill pregnant women were observed to have metabolic acidosis. Since maternal acidosis (potential of hydrogen [pH] < 7.25) is generally poorly tolerated by the foetus and progressive maternal acidosis portends the development of a non-reassuring foetal heart rate tracing, our practice is to temporise maternal acidosis by raising the maternal pH closer to 7.4 with intravenous infusion of sodium bicarbonate (150 mEq of sodium bicarbonate in 1 L of 5% dextrose in water).^[4] Those with haemodynamic instability were administered weight-based norepinephrine infusions for a mean arterial pressure goal of greater than 65 mmHg. Parturients were placed on continuous external foetal heart monitoring, with a labour and delivery nurse present at the intensive care unit (ICU) bedside.

The following data were obtained from the electronic medical records: maternal demographics, ventilator/ extracorporeal membrane oxygenation requirements, maternal serial arterial blood gases, neonatal cord gases, APGAR scores, neonatal oxygen requirement and length of neonatal ICU stay. In addition, we obtained maternal comorbidities, indication for delivery, mode and location of delivery, maternal haemodynamics, use of vasopressors, sodium bicarbonate, sedative medications, neuromuscular blockade and predelivery vital signs (pulse rate, blood pressure).

Linear regression was performed using R version 4.03 (R Core Team, Vienna, Austria) to assess the relationship among mPaCO₂, pH, arterial partial pressure of oxygen (PaO₂), bicarbonate and the corresponding variable of umbilical artery and vein (primary outcome). Linear regression was also used to examine the relationship between mPaCO, and APGAR scores at 1 and 5 min (secondary outcome). Linear regression and Pearson's correlation coefficients were used to investigate the correlation among mPaCO₂, norepinephrine dosage, number of days on a norepinephrine infusion and APGAR scores at 1 and 5 min. A Welch two-sample *t*-test was used to determine if there was any difference in 1- and 5-min APGAR scores with maternal norepinephrine use. Categorical variables were summarised with numbers and percentages, and continuous variables were described using mean and standard deviation. The median and interguartile range (IQR) were used to describe non-normally distributed variables.

There was no *a priori* power calculation or participant recruitment, and all eligible patients were included during the study period. The sample size was determined by the availability of data when this research was initially conceptualised. However, based on an earlier study of correlations between mPaCO₂ and cord venous partial pressure of carbon dioxide (PCO₂; R = 0.81) during elective caesarean in healthy pregnant women with two-tailed significance criteria of alpha = 0.05 and power = 0.80, the minimal sample size needed with this effect size is 8.^[5] Our correlations were lower in critically ill parturients than in historically healthy subjects.^[5] With our observed mPaCO₂ and umbilical vein PCO₂ values (R = 0.55), a power calculation with the same alpha and beta values would have yielded a required sample size of 24, and we did have an adequate number of patients in our sample.

RESULTS

Twenty-five parturients were delivered while they were mechanically ventilated, with four (16%) on VV-ECMO. The primary cause of ARDS was coronavirus disease 2019. Seven of the women failed maximal high-flow nasal cannula settings. They were urgently taken to the operating room (OR) for planned tracheal intubation and initiation of mechanical ventilation, followed by immediate delivery of the neonate. The remaining 18 women were mechanically ventilated for 0-30 (IQR 8) days before delivery. Twenty-four parturients underwent caesarean delivery (CD), and one patient had a spontaneous vaginal delivery in the ICU. Seven CDs were performed emergently at the bedside in the ICU, and the remaining 17 CDs were in the OR. The major indications for delivery included worsening maternal respiratory status, non-reassuring foetal heart rate and foetal bradycardia. The gestational age at the time of delivery was 32.5 (3.4) weeks. Table 1 shows the maternal and neonatal data. Table 2 shows the predelivery maternal and cord gas values.

There was a positive relationship between predelivery mPaCO₂ and umbilical vein and artery PCO₂ [Figure 1a and b] R = 0.55 ($R^2 = 0.26$, P = 0.013) and R = 0.6 ($R^2 = 0.328$, P = 0.005). Umbilical cord venous PCO₂ exceeded predelivery mPaCO₂ by 17.5 (7.5) mmHg. Figure 1c and d shows a significant negative correlation between mPaCO₂ and APGAR scores at 1 min, R = -0.55 ($R^2 = 0.268$, P = 0.006), and APGAR scores at 5 min, R = -0.56 ($R^2 = 0.284$, P = 0.004). In our sample, an mPaCO₂ of 40 mmHg was associated with APGAR scores less than 4 and 6 at 1 and 5 min, respectively, while an mPaCO₂ of 45 mmHg was associated with APGAR scores less than 3 and 5 at 1 and 5 min, respectively.

APGAR scores at 1 and 5 min were also inversely associated with the nadir maternal PaO_2 at any time point between admission and delivery, R = 0.54 ($R^2 = 0.259$, P = 0.006) and R = 0.52 ($R^2 = 0.243$ and P = 0.007), respectively.




Figure 1: Linear regression models of the closest maternal partial pressure of arterial carbon dioxide (PaCO₂) to delivery with (a) umbilical vein partial pressure of carbon dioxide (PCO₂) at delivery, (b) umbilical artery PCO₂ at delivery and (c) APGAR scores at 1 min and (d) 5 min

Maternal age (years), mean (SD) [range] 31 (6) [20-42] Gestational age on admission (weeks.days), mean (SD) [range] 32.5 (3.4) [26.2-37.3	Table 1: Maternal and neonatal characteristics		
Gestational age on admission (weeks.days), mean (SD) [range] 32.5 (3.4) [26.2-37.3 BMI (kg/m ²), mean (SD) [range] 32.8 (6.6) [226.5-17.3 BMI (kg/m ²), median (IQR) 20 (IQR 3.8-36.2) Norepinephrine required 4 Days on ECMO before delivery, median (IQR) 32 (IQR 26-40.8) Days on a ventilator before delivery, median (IQR) 32 (IQR 26-40.8) Days on a ventilator before delivery, median (IQR) 13.5 (IQR 8.0-17) Comorbidities 10 Obesity 16 Advanced maternal age 10 Gestational diabetes 1 Type 2 diabetes 2 Chronic hypertension 1 Gestational hypertension 1 Precelampsia 1 Mid asthma 5 Sickle cell disease 2 Sectational hypertension 1 Propofol 25 Etomidate 3 Dexmedetomidine 6 Midazolam 7 Fentanyl 14 Hydromorphone 3 Bicarbonate infusion 8<	Maternal characteristics	Total parturients (n=25)	
BMI (kg/m²), mean (SD) [range] 35.8 (6.6) [26.6–51.7 Maternal length of stay (days), median (IQR) 20 (IQR 3.8–36.2) Drepinepthrine required 12 ECMO required 4 Days on a vertilator before delivery, median (IQR) 32 (IQR 26–40.8) Days on a vertilator before delivery, median (IQR) 13.5 (IQR 26–40.8) Days on a vertilator before delivery, median (IQR) 16 Advanced maternal age 10 Gestational diabetes 4 Type 2 diabetes 2 Chronic hypertension 1 Gestational hypertension 1 Precelampsia 1 Mild asthma 5 Sickle cell disease 1 Scikle cell disease 1 Propofol 25 Etomidate 3 Dexmedetomidine 8 MAP range (low to high), mean (SD) 71 (7) to 95 (15) Caesarean delivery 24 Delivery location 7 Operating room 18 ICU bedside 7 Race/ethnicity 7	Maternal age (years), mean (SD) [range]	31 (6) [20–42]	
Maternal length of stay (days), median (IQR) 20 (IQR 3.8–36.2) Norepinephrine required 12 ECMO required 32 (IQR 2.6–40.8) Days on ECMO before delivery, median (IQR) 13.5 (IQR 8.0–17) Comorbidites 16 Obesity 16 Advanced maternal age 10 Gestational diabetes 2 Type 2 diabetes 2 Chronic hypertension 1 Gestational hypertension 1 Preeclampsia 1 Mid astma 5 Sickle cell disease 1 Propofol 2 Etomidate 3 Dezmedetomidine 6 Midazolam 7 Propofol 2 Etomidate 3 Dezmedetomidine 8 MAP range (iow to high), mean (SD)		32.5 (3.4) [26.2–37.3]	
Norepinephrine required12ECMO required4Days on ECMO before delivery, median (IQR)22 (IQR 26-40.8)Days on a ventilator before delivery, median (IQR)13.5 (IQR 8.0-17)Comorbidities16Obesity16Advanced maternal age10Gestational diabetes4Type 2 diabetes2Chronic hypertension1Gestational hypertension1Precedampsia1Mild asthma5Sickle cell disease1Sedation/analgesia1Propofol25Etomidate3Desmedetomidine6Midazolam7Fentanyl14Hydromorphone3Bicarbonate infusion8MAP range (low to high), mean (SD)71 (7) to 95 (15)Caesarean delivery24Delivery location7Race/ethnicity7Arisan1Hispanic or Latino1Hispanic or Latino10White5Other26	BMI (kg/m²), mean (SD) [range]	35.8 (6.6) [26.6–51.7]	
ECMO required 4 Days on ECMO before delivery, median (IQR) 32 (IQR 26-40.8) Days on a ventilator before delivery, median (IQR) 13.5 (IQR 8.0-17) Comorbidities 10 Obesity 16 Advanced maternal age 10 Gestational diabetes 2 Type 2 diabetes 2 Chronic hypertension 1 Gestational hypertension 1 Precelampsia 1 Mild asthma 5 Sickle cell disease 1 Sedation/analgesia 1 Propofol 25 Etomidate 3 Dexmedetomidine 6 Midazolam 7 Fentanyl 14 Hydromorphone 3 Bicarbonate influsion 8 MAP range (low to high), mean (SD) 71 (7) to 95 (15) Casearean delivery 24 Delivery location 7 Operating room 18 ICU bedside 7 Asian 1	Maternal length of stay (days), median (IQR)	20 (IQR 3.8–36.2)	
Days on ZCMO before delivery, median (IQR) 32 (IQR 26-40.8) Days on a ventilator before delivery, median (IQR) 13.5 (IQR 8.0-17) Comorbidities 16 Advanced matemal age 10 Gestational diabetes 4 Type 2 diabetes 2 Chronic hypertension 1 Gestational hypertension 1 Mild asthma 5 Sickle cell disease 1 Sedation/analgesia 1 Propolo 25 Etomidate 3 Description 2 Midazolam 7 Fentanyl 14 Hydromorphone 3 Bicarbonate infusion 8 MAP range (low to high), mean (SD) 71 (7) to 95 (15) Casarean delivery 24 Delivery location 18 ICU bedside 7 Ariaan 1 Hispanic or Latino 7 Mice 5 Other 5	Norepinephrine required	12	
Days on a ventilator before delivery, median (IQR)13.5 (IQR 8.0–17)Comorbidities10Obesity16Advanced maternal age10Gestational diabetes4Type 2 diabetes2Chronic hypertension1Gestational hypertension1Precelampsia1Mild asthma5Sickle cell disease1Sedation/analgesia25Propofol25Etomidate6Midazolam7Fentanyl14Hydromorphone3Bicarbonate infusion8MAP range (low to high), mean (SD)71 (7) to 95 (15)Caesarean delivery24Delivery location7Arian1Hispanic or Latino7Mina function1Hispanic or Latino10While5Other2	ECMO required	4	
Comorbidities 16 Advanced maternal age 10 Gestational diabetes 4 Type 2 diabetes 2 Chronic hypertension 1 Gestational hypertension 1 Gestational hypertension 1 Precelampsia 1 Mild asthma 5 Sickle cell disease 1 Sedation/analgesia 7 Propofol 25 Etomidate 3 Dexmedetomidine 6 Midazolam 7 Fentanyl 14 Hydromorphone 3 Bicarbonate infusion 8 MAP range (low to high), mean (SD) 71 (7) to 95 (15) Casasraen delivery 24 Delivery location 7 Operating room 18 ICU bedside 7 Arican American 7 Asian 1 Hispanic or Latino 10 White 5	Days on ECMO before delivery, median (IQR)	32 (IQR 26–40.8)	
Obesity 16 Advanced maternal age 10 Gestational diabetes 4 Type 2 diabetes 2 Chronic hypertension 1 Gestational hypertension 1 Precelampsia 1 Mild asthma 5 Sickle cell disease 1 Propofol 25 Etomidate 3 Dexmedetomidine 6 Midazolam 7 Fentanyl 14 Hydromorphone 3 Bicarbonate infusion 8 MAP range (low to high), mean (SD) 71 (7) to 95 (15) Caesarean delivery 24 Delivery location 7 Acce/ethnicity 7 Arican American 7 Asian 1 Hispanic or Latino 7 White 5 Other 2	Days on a ventilator before delivery, median (IQR)	13.5 (IQR 8.0–17)	
Advanced maternal age 10 Gestational diabetes 4 Type 2 diabetes 2 Chronic hypertension 1 Gestational hypertension 1 Precedampsia 1 Mid asthma 5 Sickle cell disease 1 Sedation/analgesia 1 Propofol 25 Etomidate 3 Dexmedetomidine 6 Midazolam 7 Fentanyl 14 Hydromorphone 3 Bicarbonate infusion 8 MAP range (low to high), mean (SD) 71 (7) to 95 (15) Caesarean delivery 24 Delivery location 7 Operating room 18 ICU bedside 7 Arian American 7 Asian 1 Hispanic or Latino 5 Other 2	Comorbidities		
Gestational diabetes4Type 2 diabetes2Chronic hypertension1Gestational hypertension1Preeclampsia1Mild asthma5Sickle cell disease1Sedation/analgesia25Propofol25Etomidate3Dexmedetomidine6Midazolam7Fentanyl14Hydromorphone3Bicarbonate infusion8MAP range (low to high), mean (SD)71 (7) to 95 (15)Caesarean delivery24Delivery location7Race/ethnicity7Arian1Hispanic or Latino3White5Other20	Obesity	16	
Gestational diabetes4Type 2 diabetes2Chronic hypertension1Gestational hypertension1Preeclampsia1Mild asthma5Sickle cell disease1Sedation/analgesia25Propofol25Etomidate3Dexmedetomidine6Midazolam7Fentanyl14Hydromorphone3Bicarbonate infusion8MAP range (low to high), mean (SD)71 (7) to 95 (15)Caesarean delivery24Delivery location7Race/ethnicity7Arian American7Asian1Hispanic or Latino3Other20	Advanced maternal age	10	
Chronic hypertension1Gestational hypertension1Precclampsia1Mild asthma5Sickle cell disease1Sedation/analgesia25Propofol25Etomidate3Dexmedetomidine6Midazolam7Fentanyl14Hydromorphone3Bicarbonate infusion8MAP range (low to high), mean (SD)71 (7) to 95 (15)Caesarean delivery24Delivery location7Operating room18ICU bedside7Race/ethnicity1African American7Asian1Hispanic or Latino10White5Other2		4	
Chronic hypertension1Gestational hypertension1Precclampsia1Mild asthma5Sickle cell disease1Sedation/analgesia25Propofol25Etomidate3Dexmedetomidine6Midazolam7Fentanyl14Hydromorphone3Bicarbonate infusion8MAP range (low to high), mean (SD)71 (7) to 95 (15)Caesarean delivery24Delivery location7Operating room18ICU bedside7Race/ethnicity1African American7Asian1Hispanic or Latino10White5Other2	Type 2 diabetes	2	
Gestational hypertension1Preeclampsia1Mild asthma5Sickle cell disease5Sickle cell disease25Stedation/analgesia3Propofol25Etomidate3Dexmedetomidine6Midazolam7Fentanyl14Hydromorphone3Bicarbonate infusion8MAP range (low to high), mean (SD)71 (7) to 95 (15)Caesarean delivery24Delivery location7Coperating room18ICU bedside7Race/ethnicity1African American7Asian1Hispanic or Latino10White5Other2			
Preeclampsia 1 Mild asthma 5 Sickle cell disease 1 Sedaton/analgesia 25 Propofol 25 Etomidate 3 Dexmedetomidine 6 Midazolam 7 Fentanyl 14 Hydromorphone 3 Bicarbonate infusion 8 MAP range (low to high), mean (SD) 71 (7) to 95 (15) Caesarean delivery 24 Delivery location 18 ICU bedside 7 Race/ethnicity 7 Arican American 7 Asian 1 Hispanic or Latino 10 White 5 Other 2		1	
Mild asthma5Sickle cell disease1Sedation/analgesia25Propofol25Etomidate3Dexmedetomidine6Midazolam7Fentanyl14Hydromorphone3Bicarbonate infusion8MAP range (low to high), mean (SD)71 (7) to 95 (15)Caesarean delivery24Delivery location18ICU bedside7Race/ethnicity1African American7Asian1Hispanic or Latino10White5Other2			
Sickle cell disease1Sedation/analgesia25Propofol25Etomidate3Dexmedetomidine6Midazolam7Fentanyl14Hydromorphone3Bicarbonate infusion8MAP range (low to high), mean (SD)71 (7) to 95 (15)Caesarean delivery24Delivery location18ICU bedside7Race/ethnicity1African American7Asian1Hispanic or Latino10White5Other2			
Sedation/analgesia25Propofol25Etomidate3Dexmedetomidine6Midazolam7Fentanyl14Hydromorphone3Bicarbonate infusion8MAP range (low to high), mean (SD)71 (7) to 95 (15)Casarean delivery24Delivery location18ICU bedside7Race/ethnicity7African American7Hispanic or Latino10White5Other2			
Propofol 25 Etomidate 3 Dexmedetomidine 6 Midazolam 7 Fentanyl 14 Hydromorphone 3 Bicarbonate infusion 8 MAP range (low to high), mean (SD) 71 (7) to 95 (15) Casarean delivery 24 Delivery location 18 ICU bedside 7 Race/ethnicity 1 African American 7 Asian 1 Hispanic or Latino 10 White 5 Other 2			
Etomidate3Dexmedetomidine6Midazolam7Fentanyl14Hydromorphone3Bicarbonate infusion8MAP range (low to high), mean (SD)71 (7) to 95 (15)Caesarean delivery24Delivery location18ICU bedside7Race/ethnicity7African American7Asian1Hispanic or Latino10White5Other2		25	
Dexmedetomidine6Midazolam7Fentanyl14Hydromorphone3Bicarbonate infusion8MAP range (low to high), mean (SD)71 (7) to 95 (15)Caesarean delivery24Delivery location18ICU bedside7Race/ethnicity7African American7Hispanic or Latino10White5Other2			
Midazolam7Fentanyl14Hydromorphone3Bicarbonate infusion8MAP range (low to high), mean (SD)71 (7) to 95 (15)Caesarean delivery24Delivery location18ICU bedside7Race/ethnicity7African American7Asian1Hispanic or Latino10White5Other2			
Fentanyl14Hydromorphone3Bicarbonate infusion8MAP range (low to high), mean (SD)71 (7) to 95 (15)Caesarean delivery24Delivery location18Operating room18ICU bedside7Race/ethnicity7African American7Asian1Hispanic or Latino10White5Other2			
Hydromorphone3Bicarbonate infusion8MAP range (low to high), mean (SD)71 (7) to 95 (15)Caesarean delivery24Delivery location18ICU bedside7Race/ethnicity7African American7Asian1Hispanic or Latino10White5Other2			
Bicarbonate infusion8MAP range (low to high), mean (SD)71 (7) to 95 (15)Caesarean delivery24Delivery location24Operating room18ICU bedside7Race/ethnicity7African American7Asian1Hispanic or Latino10White5Other2			
MAP range (low to high), mean (SD)71 (7) to 95 (15)Caesarean delivery24Delivery location18Operating room18ICU bedside7Race/ethnicity7African American7Asian1Hispanic or Latino10White5Other2			
Caesarean delivery24Delivery location18Operating room18ICU bedside7Race/ethnicity7African American7Asian1Hispanic or Latino10White5Other2			
Delivery location18Operating room18ICU bedside7Race/ethnicity7African American7Asian1Hispanic or Latino10White5Other2			
Operating room18ICU bedside7Race/ethnicity7African American7Asian1Hispanic or Latino10White5Other2		24	
ICU bedside7Race/ethnicity7African American7Asian1Hispanic or Latino10White5Other2			
Race/ethnicity7African American7Asian1Hispanic or Latino10White5Other2			
African American7Asian1Hispanic or Latino10White5Other2		1	
Asian1Hispanic or Latino10White5Other2		_	
Hispanic or Latino10White5Other2			
White5Other2			
Other 2	•		
	White		
Neonatal characteristics Total neonates (n=26)			
	Neonatal characteristics	Total neonates (n=26)	
Weight at birth (g), mean (SD) 2034 (651)	Weight at birth (g), mean (SD)		
NICU length of stay (days), median (IQR) 23 (IQR 11.3–34.3)	NICU length of stay (days), median (IQR)	23 (IQR 11.3–34.3)	
Respiratory support	Respiratory support		
Intubation 13	Intubation	13	
CPAP 10	CPAP	10	
None 3	None	3	
APGAR score	APGAR score		
1 min, median (IQR) 4 (IQR 2–5)	1 min, median (IQR)	4 (IQR 2–5)	
5 min, median (IQR) 7 (IQR 4.3–8.0)	5 min, median (IQR)		

Mean, SD or median (IQR Q1–Q3), except for categorical data presented as several patients. Norepinephrine infusions were weight-based dosing of 0.01–0.25 µg/kg/min. BMI=body mass index, CPAP=continuous positive airway pressure, ECMO=extracorporeal membrane oxygenation, ICU=intensive care unit, IQR=interquartile range, MAP=mean arterial pressure, NICU=neonatal intensive care unit, SD=standard deviation

There was no significant difference in APGAR scores at 1 or 5 min in parturients who required a norepinephrine infusion compared to those who did not. Furthermore, APGAR scores at 1 and 5 min did not correlate with the dosage or number of days of maternal norepinephrine usage.

DISCUSSION

A positive correlation between maternal and umbilical cord PCO_2 observed in this study reinforces earlier findings by Baraka,^[5] Newman *et al.*^[6] and Ivankovic *et al.*,^[2] suggesting umbilical venous PCO_2 can be

Table 2: Maternal ABG and umbilical cord gases			
	Umbilical artery	Umbilical vein	Maternal ABG predelivery
pН	7.22 (0.06) (7.19, 7.24)	7.26 (0.05) (7.24, 7.28)	7.37 (0.08) (7.33, 7.40)
Normal values	7.12–7.35	7.23–7.44	7.2–7.52
PO ₂ (mmHg)	20.2 (5.15) (18.1, 22.2)	29.3 (13.2) (24, 34.6)	123.8 (39.4) (108, 139.5)
Normal values	6–27.6	16.4–40	80–100
PCO ₂ (mmHg)	62.1 (10.9) (57.7, 66.5)	55 (11.8) (50.2, 59.7)	36.9 (6.9) (34.2, 39.7)
Normal values	41.9–73.5	28.8–53.3	28–32
HCO ₃ (mmol/L)	24.7 (3.9) (23.1, 26.2)	24 (3.5) (22.6, 25.4)	20.8 (4.16) (19.1, 22.5)
Normal values	18.8–28.2	17.2–25.6	18–21

Data are Expressed as mean (standard deviation) (95% confidence interval). ABG=Arterial blood gases, PCO₂=Partial pressure of carbon dioxide, PO₂=Partial pressure of oxygen, pH: Potential of hydrogen, HCO3: Bicarbonate

predicted from mPaCO₂ status. However, our observed correlation in critically ill pregnant women was lower than that observed in healthy pregnant women during caesarean section. Newman et al.^[6] determined the relationship between maternal capillary PCO, and foetal scalp PCO₂ in 68 healthy women during labour. The correlation coefficient was 0.476 (P < 0.01), akin to our findings. The foetal-maternal PCO, gradient during the first stage of labour was 8.8 mmHg; during the second stage, it was 15.3 mmHg. Five of these 68 healthy parturients were hyperventilated to induce maternal hypocarbia, and five inhaled 7.6% carbon dioxide in oxygen (carbogen) to induce hypercarbia. During hyperventilation, the foetal PCO, exceeded mPaCO, by 14 (range 8-21) mmHg (control 11.4 mmHg), while during carbogen inhalation, the foetal PCO, exceeded the maternal PCO, by 6.7 (range 2–22) mmHg (control 11.2 mmHg, maternal capillary PaCO₂ 43.8 mmHg during carbogen inhalation). Ivankovic et al.^[2] studied the relationship between mPaCO, and foetal cord venous PCO, in healthy pregnant women at vaginal assisted delivery under methoxyflurane anaesthesia. Hypercarbia was induced in 15 women by removing a carbon dioxide circle absorber from the anaesthesia breathing system. Fifteen women had standard methoxyflurane anaesthesia with a circle absorber in place. The other 15 women had saddle blocks for vaginal assisted delivery. The mean cord blood venous PCO, and mPaCO, gradient was 8 mmHg in normocarbia pregnant women, 1 mmHg in the hypercarbia group ($PaCO_2 = 57.6$ [8.8] mmHg) and 4 mmHg in the saddle block group. On the contrary, in our study, the foetal cord venous PCO₂ exceeded mPaCO₂ by approximately 17.5 (7.5) mmHg, which is higher than the values observed by both Newman et al.^[6] and Ivankovic et al.^[2] in healthy pregnant women in labour. The exaggerated difference is most likely due to experimentally induced hypercarbia by carbon dioxide inhalation during normal labour in the above studies versus prolonged hypercarbia due to critical respiratory illness with other compounding factors such as infection in the parturients of this study. Nonetheless, the foetal blood gas PCO_2 is predictable from maternal PCO_2 values in critically pregnant women.

Neonatal outcomes were the secondary aim of our study. Maternal hypercarbia >45 mmHg at delivery may be associated with lower 1- and 5-min APGAR scores (<3 at 1 min and <5 at 5 min) [Figure 1c and d]. These findings suggest that the current threshold of permissive hypercarbia of a PaCO₂ of 50 mmHg may be too high, disrupting CO₂ elimination from the foetus, which has a limited ability to buffer excessive amounts of CO₂.^[3,6] Our study's higher PCO₂ in the cord arterial blood demonstrates this.

The current threshold of PaCO, of 50 mmHg was extrapolated from Ivankovic et al.'s^[2] study of iatrogenically induced transient (<10 min) hypercarbia up to 57 mmHg during methoxyflurane anaesthesia for vaginal assisted delivery as described above. Babies in the hypercarbia group had higher APGAR scores than those in the other groups. The higher APGAR scores were attributed to hypercarbia causing higher cardiac output, increased uteroplacental blood flow, relaxation of the uterus and a leftward shift of the oxyhaemoglobin dissociation curve.^[2] Indeed, this study's conclusions did not apply to our study parturients with ongoing critical illnesses for an extended duration and necessitated administration of other concomitant drugs.^[7] Concurrent medications, such as fentanyl, midazolam and propofol, are necessary to facilitate mechanical ventilation in the parturients, and these drugs affect the neonatal outcomes. Furthermore, the induced hypercarbia in the study of Ivankovic *et al.*^[2] was transient compared to the relatively longer-lasting hypercarbia in our critically ill study population. Another case series reviewed five parturients with status asthmaticus, where mPaCO₂ ranged from 31 to 132 mmHg during pregnancy. However, the parturients with higher $PaCO_2$ were in early pregnancy (less than 14 weeks) and those beyond 27 weeks had normal $PaCO_2$. Therefore, the findings of this study do not apply to parturients requiring extended mechanical ventilation.^[8]

It is indeed difficult to separate the effects of high maternal and foetal PCO_2 versus the impact of concomitant factors intrinsic to critical patients, such as drugs, infection and vasopressor support, on the neonatal outcome. However, it must be noted that many of the parturients with lower mPaCO₂ also received sedative drugs and vasopressor support. The aetiology of lower APGAR scores may be debatable. However, it is indisputable that clinicians must be prepared to expect babies with lower APGAR scores and to assist and support newborns with lower APGAR scores at delivery in critically ill pregnant women in whom mPaCO₂ is high.

Lower nadir predelivery maternal PaO_2 values during the period between admission and delivery also predicted lower APGAR scores at 1 and 5 min, suggesting oxygen delivery to the foetus is also a critical factor in the neonatal outcome. However, the PaO_2 value closest to delivery was within the normal range for all patients in our case series. Maternal pH did not predict APGAR scores, possibly due to the sodium bicarbonate infusions that normalise metabolic acidosis.

There were a few limitations of this study. This was a retrospective study with a small sample size. Several uncontrollable factors inherent to critically ill parturients influence neonatal APGAR scores. Many parturients received midazolam, fentanyl and propofol infusions for sedation while on mechanical ventilation, and these may affect the APGAR scores. Haemodynamic factors can also influence neonatal outcomes. While the parturients' haemodynamic parameters were maintained within a reasonable range, 48% of the women received norepinephrine infusion around or during the predelivery period. Extended use of vasopressors can influence uteroplacental blood flow and neonatal outcomes. However, no statistically significant relationship was found for maternal norepinephrine use, including when accounting for the dosage and days of norepinephrine usage. Furthermore, a large portion of patients in our series were African American (28%) and/or Hispanic (40%), which may be reflective of the racial/ethnic disparities in maternal morbidity and mortality.^[9] Finally, we do not have data to inform conclusions on the possible implications for the long-term neonatal outcomes in babies with lower APGAR scores.

CONCLUSION

The mPaCO₂ predicts cord PCO₂ during mechanical ventilation of critically ill pregnant women. However, the difference between the two is exaggerated in this group of parturients. We found an inverse relationship between rising mPaCO₂ levels and neonatal APGAR scores, at least in critically ill pregnant women with many compounding factors.

Financial support and sponsorship Nil.

Conflicts of interest

There are no conflicts of interest.

ORCID

Katelyn Scharf: https://orcid.org/000-0003-4125-3410 Shobana Bharadwaj: https://orcid.org/0000-0003-2487-1372

Allison Lankford: https://orcid.org/0000-0002-6609-6944

Michael Wong: https://orcid.org/0000-0002-9697-9799 Bhavani Shankar Kodali: https://orcid.org/000-0002-2683-4359

REFERENCES

- 1. Bandi VD, Munnur U, Matthay MA. Acute lung injury and acute respiratory distress syndrome in pregnancy. Crit Care Clin 2004;20:577-607.
- 2. Ivankovic AD, Elam JO, Huffman J. Effect of maternal hypercarbia on the newborn infant. Am J Obstet Gynecol 1970;107:939-46.
- Lapinsky SE. Acute respiratory failure in pregnancy. Obstet Med 2015;8:126-32.
- 4. Wong MJ, Bharadwaj S, Galey JL, Lankford AS, Galvagno S, Kodali BS. Extracorporeal membrane oxygenation for pregnant and postpartum patients. Anesth Analg 2022;135:277-89.
- 5. Baraka A. Correlation between maternal and foetal PO_2 and PCO_2 during cesarean section. Br J Anaesth 1970;42:434-8.
- Newman W, Braid D, Wood C. Fetal acid-base status. 1. Relationship between maternal and fetal pCO2. Am J Obstet Gynecol 1967;97:43-51.
- Omo-Aghoja L. Maternal and fetal Acid-base chemistry: A major determinant of perinatal outcome. Ann Med Health Sci Res 2014;4:8-17.
- 8. Elsayegh D, Shapiro JM. Management of the obstetric patient with status asthmaticus. J Intensive Care Med 2008;23:396-402.
- 9. Small MJ, Allen TK, Brown HL. Global disparities in maternal morbidity and mortality. Semin Perinatol 2017;41:318-22.